Threat Of SREs From Bone Metastases Increases As New Treatments In Prostate Cancer Extend Survival

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

About ZOMETA: defend against SREs across a broad range of tumor types

PAGE

1 2

As new treatments extend survival, the threat of SREs increases

For patients with good performance status and metastatic disease confined to the axial skeleton, median survival is more than 4 years⁴
Without treatment, the median time to first SRE in men with bone metastases from prostate cancer is less than 11 months²

Median time to first SRE vs median survival in advanced prostate cancer^2,4

*Median survival in men with good performance status and disease
confined to bone that affects the axial skeleton (treatment regimen
not specified).

PAGE

1 2

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US flag at the top right corner of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.